

Clinical trials of anticoagulant for acute coronary syndrome in ACS (excluding AMI)

TrialResults-center www.trialresultscenter.org

1 oral anticoagulant

| Trial | Treatments | Patients | Trials design and methods |
|---|---|----------------------------|--|
| coumadin vs control (on top of aspirin) | | | |
| ASPECT-2 (coumadin+asp vs asp) , 2002 n=333/336 follow-up: 1 year | coumadin(INR mean 2.4) +aspirin versus aspirin | UA, AMI | open the Netherlands |
| warfarin vs control (on top of aspirin) | | | |
| ATACS (pilot study) (warfarin vs control) , 1990 n=37/32 follow-up: 65279;3 months | heparin/warfarin target INR 65279;3-4.5 + aspirin versus aspirin alone | 65279;UA, NSTEMI | open |
| ATACS , 1994 n=105/109 follow-up: 3 months | heparin/warfarin (INR median 2.3) + aspirin versus aspirin | UA, NSTEMI | open |
| OASIS Pilot (phase 1) , 1998 n=155/154 follow-up: 6 months | warfarin 3mg/d for 6 months (INR mean 1.5) versus control | UA, NSTEMI | open |
| OASIS Pilot (phase 2) , 1998 n=98/99 follow-up: 3 months | warfarin adjusted dose (INR mean 2.3) for 3 months versus standard treatment | UA, NSTEMI | open |
| OASIS-2 Warfarin Substudy , 2001 n=1848/1864 follow-up: 5 months | warfarin target INR 65279;22.5 for 5 months +aspirin versus control | UA | open |
| warfarin vs placebo (on top of aspirin) | | | |
| Huyhn , 2001 n=44/46 follow-up: 1 year | warfarin adjusted dose for INR 22.5 +aspirin versus placebo +aspirin | UA, NSTEMI with prior CABG | double blind |
| coumadin vs aspirin | | | |
| ASPECT-2 (coumadin vs aspirin) , 2002 n=325/336 follow-up: 1 year (range 0-26 months) | coumadin (phenprocoumon or acenocoumarol) target INR 3-4) versus aspirin 80mg daily | UA, AMI | Parallel groups open the Netherlands |
| warfarin vs aspirin | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|---|------------------|---------------------------|
| ATACS (pilot study) warfarin vs aspirin , 1990 n=24/32 follow-up: 65279;3 months | heparin/warfarin target INR 65279;3-4 versus aspirin 65279;325 mg daily | 65279;UA, NSTEMI | open |

References

ASPECT-2 (coumadin+asp vs asp), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. *Lancet* 2002;360:109-13 [[12126819](#)]

ATACS (pilot study) (warfarin vs control), 1990:

Cohen M, Adams PC, Hawkins L, Bach M, Fuster V Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). *Am J Cardiol* 1990;66:1287-92 [[2244556](#)]

ATACS, 1994:

Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KA, Chesebro JH, Strain J, Keller C Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. *Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation* 1994;89:81-8 [[8281698](#)]

OASIS Pilot (phase 1), 1998:

Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. *Circulation* 1998;98:1064-70 [[9736592](#)]

OASIS Pilot (phase 2), 1998:

Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. *Circulation* 1998;98:1064-70 [[9736592](#)]

OASIS-2 Warfarin Substudy, 2001:

Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. *J Am Coll Cardiol* 2001;37:475-84 [[11216966](#)]

Huyhn, 2001:

Huynh T, Throux P, Bogaty P, Nasmith J, Solymoss S Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. *Circulation* 2001;103:3069-74 [[11425770](#)]

ASPECT-2 (coumadin vs aspirin), 2002:

ATACS (pilot study) warfarin vs aspirin, 1990:

Cohen M, Adams PC, Hawkins L, Bach M, Fuster V Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). *Am J Cardiol* 1990;66:1287-92 [[2244556](#)]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.